R-Spondin1 protects gastric stem cells and mitigates gastric GVHD in allogeneic hematopoietic stem cell transplantation.

"Conflict-of-interest disclosure: T.T. is a recipient of research grants from 10.13039/501100004095Kyowa Kirin, 10.13039/100010795Chugai, 10.13039/100018142Fuji Pharma, 10.13039/100018036Nippon Shinyaku, Asahi Kasei Pharma, 10.13039/501100003769Eisai, Sumitomo Pharma, ONO Pharmaceutical Co, Ltd, 10.13039/501100004948Astellas, 10.13039/501100005612Shionogi, Priothera SAS, LUCA Science, and Otsuka Co, Ltd; and has served as a consultant or advisory board member for Novartis, Meiji Seika Pharma, Daiichi Sankyo, Asahi Kasei Pharma, Astellas, AstraZeneca, Takeda, Janssen, Roche, Diagnostics, Sumitomo Pharma, Celgene, and Sanofi. The remaining authors declare no competing financial interests."

"This study was supported by grants from 10.13039/501100001700MEXT/10.13039/501100001700JSPS KAKENHI (20K21610 and 21H02944 [T.T.], 18K16104 [E.H.], 21K16259 [T.A.], and 20K17366 [H.O.]), and the 10.13039/501100009033Center of Innovation Program from JST (T.T.). Conflict-of-interest disclosure: T.T. is a recipient of research grants from 10.13039/501100004095Kyowa Kirin, 10.13039/100010795Chugai, 10.13039/100018142Fuji Pharma, 10.13039/100018036Nippon Shinyaku, Asahi Kasei Pharma, 10.13039/501100003769Eisai, Sumitomo Pharma, ONO Pharmaceutical Co, Ltd, 10.13039/501100004948Astellas, 10.13039/501100005612Shionogi, Priothera SAS, LUCA Science, and Otsuka Co, Ltd; and has served as a consultant or advisory board member for Novartis, Meiji Seika Pharma, Daiichi Sankyo, Asahi Kasei Pharma, Astellas, AstraZeneca, Takeda, Janssen, Roche, Diagnostics, Sumitomo Pharma, Celgene, and Sanofi. The remaining authors declare no competing financial interests."